Crystal Comfort s.r.o.
- Address
- lock Available on a paid plan
Nervous System Diseases
The psychiatric ambulatory unit at Crystal Comfort s.r.o. conducts extensive research on neurodegenerative conditions, especially Alzheimer’s disease and related cognitive impairments. Trials aim to evaluate new therapies that reduce agitation, psychosis, and functional decline in patients with mild dementia or early Alzheimer’s.
- Agitation associated with Alzheimer’s dementia
- Psychosis associated with Alzheimer’s disease
- Mild cognitive impairment or mild dementia of the Alzheimer’s type
- Hallucinations and delusions in Alzheimer’s disease
Across 20 clinical trials and 4 investigators, the site focuses on improving safety and efficacy outcomes for neuro‑behavioral symptoms in elderly populations.
Behavioral Disciplines and Activities
Research in this area targets disruptive behavioral symptoms that affect quality of life for patients with psychiatric and neurocognitive disorders. The goal is to test interventions that mitigate agitation, aggression, and other challenging behaviors.
- Agitation in patients with dementia of the Alzheimer’s type
- Behavioral pathology in Alzheimer’s disease
- Hallucinations and delusions as behavioral disturbances
- Mania with mixed features in bipolar‑I disorder
The program emphasizes novel agents and combination strategies to provide safer, more effective behavioral management.
Mental Disorders
The site’s portfolio includes multiple studies on mood and psychotic illnesses such as major depressive disorder, schizophrenia, and bipolar‑I disorder. Trials are designed to assess adjunctive treatments, improve symptom control, and enhance long‑term tolerability.
- Major depressive disorder with insomnia symptoms
- Negative symptoms of schizophrenia
- Manic episodes in bipolar‑I disorder
- Generalized anxiety disorder with inadequate response
- Depression with anxious distress
By integrating new pharmacologic options, the research seeks to address unmet needs in chronic mental health care.
Psychological Phenomena
Studies under this theme explore core psychological experiences such as anxiety, agitation, and cognitive distress across various diagnoses. The objective is to identify therapies that alleviate these symptoms while maintaining safety.
- Generalized anxiety disorder
- Agitation associated with Alzheimer’s dementia
- Psychological distress in major depression
- Cognitive impairment in early Alzheimer’s disease
- Psychosis as a psychological phenomenon
Long‑term safety and tolerability are key endpoints, reflecting the site’s commitment to sustainable treatment outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Neurocrine Biosciences Inc.4trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Crystal Comfort s.r.o.
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety Disorder | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase IV | Not Recruiting | Sep 2023 | Sep 2025 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 4 | Unknown | 2024-05-09 | 2025-09-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.